At TargImmune, our mission is to significantly improve the survival of cancer patients.
We aim to improve survival rates by developing novel targeted anticancer therapeutics which provide a multi-pronged approach against solid tumours.
The TargImmune team are dedicated to transforming the lives of cancer patients, and all those whose lives they touch, by bringing our proprietary, first-in-class, cancer-fighting Ta:RNA™ platform to the clinic.
Our novel Ta:RNA™ platform is the first in a new class known as targeted apoptosis and immune modulators (TAIMs). It selectively destroys cancer cells by utilizing targeted nanoparticles to deliver double-stranded RNA and harness the human body’s powerful antiviral defence responses.